DK1185264T3 - Fremgangsmåde til fremstilling af amorft atorvastatin-calcium - Google Patents

Fremgangsmåde til fremstilling af amorft atorvastatin-calcium

Info

Publication number
DK1185264T3
DK1185264T3 DK00900300T DK00900300T DK1185264T3 DK 1185264 T3 DK1185264 T3 DK 1185264T3 DK 00900300 T DK00900300 T DK 00900300T DK 00900300 T DK00900300 T DK 00900300T DK 1185264 T3 DK1185264 T3 DK 1185264T3
Authority
DK
Denmark
Prior art keywords
atorvastatin calcium
preparation
solvent
amorphous atorvastatin
amorphous
Prior art date
Application number
DK00900300T
Other languages
Danish (da)
English (en)
Inventor
Yatendra Kumar
Rajesh Thaper
S M Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11091180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1185264(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of DK1185264T3 publication Critical patent/DK1185264T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00900300T 1999-05-25 2000-01-06 Fremgangsmåde til fremstilling af amorft atorvastatin-calcium DK1185264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN775DE1999 IN191236B (cg-RX-API-DMAC10.html) 1999-05-25 1999-05-25
PCT/IB2000/000014 WO2000071116A1 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium

Publications (1)

Publication Number Publication Date
DK1185264T3 true DK1185264T3 (da) 2007-08-20

Family

ID=11091180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900300T DK1185264T3 (da) 1999-05-25 2000-01-06 Fremgangsmåde til fremstilling af amorft atorvastatin-calcium

Country Status (15)

Country Link
US (2) US6528660B1 (cg-RX-API-DMAC10.html)
EP (1) EP1185264B1 (cg-RX-API-DMAC10.html)
CN (2) CN1680315A (cg-RX-API-DMAC10.html)
AT (1) ATE362759T1 (cg-RX-API-DMAC10.html)
AU (1) AU778962B2 (cg-RX-API-DMAC10.html)
BR (1) BR0010923A (cg-RX-API-DMAC10.html)
DE (1) DE60034946T2 (cg-RX-API-DMAC10.html)
DK (1) DK1185264T3 (cg-RX-API-DMAC10.html)
ES (1) ES2284472T3 (cg-RX-API-DMAC10.html)
HK (1) HK1045118A1 (cg-RX-API-DMAC10.html)
IN (1) IN191236B (cg-RX-API-DMAC10.html)
MY (1) MY133511A (cg-RX-API-DMAC10.html)
PT (1) PT1185264E (cg-RX-API-DMAC10.html)
WO (1) WO2000071116A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200109656B (cg-RX-API-DMAC10.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (cg-RX-API-DMAC10.html) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
EP1572638A4 (en) * 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EP1615884B1 (en) 2003-04-11 2016-06-29 LEK Pharmaceuticals d.d. Process for the preparation of amorphous calcium salt of atorvastatin
RU2339364C2 (ru) * 2003-04-29 2008-11-27 Н.В.Органон, Nl Способ затвердевания с применением антирастворителя
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
AU2004317570B2 (en) 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
BRPI0509923A (pt) * 2004-04-16 2007-09-18 Pfizer Prod Inc processo para formação de cálcio de atorvastatina amorfa
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006021969A1 (en) 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
ES2272206T1 (es) * 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
MX2007004722A (es) * 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
AU2005305460B2 (en) 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
WO2007052296A2 (en) * 2005-08-23 2007-05-10 Kopran Research Laboratories Ltd A process of preparing amorphous atorvastatin calcium
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101684090B (zh) * 2008-09-27 2012-12-05 广东东阳光药业有限公司 一种制备无定形阿托伐他汀钙的方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
US10138206B2 (en) * 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69634054T2 (de) * 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
DE60034946D1 (de) 2007-07-05
CN1196679C (zh) 2005-04-13
US6528660B1 (en) 2003-03-04
HK1045118A1 (zh) 2002-11-15
CN1351493A (zh) 2002-05-29
CN1680315A (zh) 2005-10-12
WO2000071116A1 (en) 2000-11-30
EP1185264A1 (en) 2002-03-13
DE60034946T2 (de) 2008-01-17
AU778962B2 (en) 2004-12-23
ATE362759T1 (de) 2007-06-15
ES2284472T3 (es) 2007-11-16
MY133511A (en) 2007-11-30
ZA200109656B (en) 2002-06-27
US20030149279A1 (en) 2003-08-07
BR0010923A (pt) 2002-07-16
EP1185264B1 (en) 2007-05-23
IN191236B (cg-RX-API-DMAC10.html) 2003-10-11
PT1185264E (pt) 2007-07-10
AU1996700A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
DK1185264T3 (da) Fremgangsmåde til fremstilling af amorft atorvastatin-calcium
CA2067711A1 (en) Solid phase extraction purification of dna
DK0897386T3 (da) Fremgangsmåde til fremstilling af et magnesiumsalt af en substitueret sulfinylheterocyklus
WO2005104711A8 (en) Purification of progesterone receptor modulators
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DE602004020674D1 (de) 1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DK0590769T3 (da) Fremgangsmåde til fjernelse af vandopløselige organiske materialer fra olieprocesvand
DE60031882D1 (de) Verfahren zur herstellung von amorphem atorvastatin kalzium
DK1349580T4 (da) Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
WO2003018547A3 (en) An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
MXPA04005603A (es) Sal cristalina de calcio del acido (r-(r*, r*) (-2- (4-fluorofenil)- (,(- dihidroxi- 5(1- metiletil)- 3-fenil -4-((fenilamino) carbonil (-1h-pirrol -heptanoico (2:1).
BR0114797B1 (pt) método para a remoção de água de um composto de organoborano úmido.
DK0719279T3 (da) Fremgangsmåde til rensning af 1-[N2-((S)-ethoxycarbonyl)-3-phenylpropyl)-N6-trifluoracetyl]-L-lysyl-L-prolin (lisinopril(Tf
DE69927044D1 (de) Verfahren zur racemizierung
DK1254110T3 (da) Proces til fremstilling af 2-hydroxy-4-methylthiosmörsyreestere
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
DK1214321T3 (da) Proces til fremstilling af naphthyridin-3-carboxylsyre-derivater
DE60016813D1 (de) Verfahren zur Reinigung einer Polycarbonatlösung
WO2006048893A3 (en) A process for synthesis of large particle size statin compounds
DK1177164T3 (da) Fremgangsmåde til oprensning af diacerein
DK1328357T3 (da) Fremgangsmåde til behandling af slagge fra affaldsforbrændingsanlæg
DK1343808T3 (da) Fremgangsmåde til syntese af et LHRA-peptid
DK0965586T3 (da) Fremgangsmåde til oprensning af carbazolesterforstadier til 6-chlor-alfa-methyl-carbazol-2-eddikesyre
ATE283367T1 (de) Verfahren zur gewinnung von bakteriorhodopsin
DE60117687D1 (de) Verfahren zur synthese von pfropfpolymeren